IP Library Granted Patent US 8,901,106
Granted Patent B2
US 8,901,106 · App. 14/006,980 · Granted Dec 2, 2014

Imidazole prodrug LXR modulators

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,901,106
App. No.
14/006,980
Granted
Dec 2, 2014
Kind
B2
Abstract

Imidazole prodrugs, pharmaceutically acceptable salts, or isomers thereof, of the invention are disclosed, which are useful as modulators of the activity of liver X receptors (LXR). Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.

Claims (14)

1. A compound, or pharmaceutically acceptable salt thereof, selected from the group consisting of:

2. A compound, or pharmaceutically acceptable salt thereof, of claim 1 which is

3. A compound, or pharmaceutically acceptable salt thereof, of claim 1 which is

4. A compound, or pharmaceutically acceptable salt thereof, which is

5. A compound, or pharmaceutically acceptable salt thereof, which is

6. The compound of claim 4 that is a pharmaceutically acceptable salt of said compound.

7. The compound of claim 6 , wherein the pharmaceutically acceptable salt comprises the di-(2-amino-2-(hydroxymethyl)propanediol)ethanolate salt.

8. A composition comprising at least one compound of claim 1 and one or more pharmaceutically acceptable carriers.

9. The composition of claim 8 further comprising at least one additional therapeutic agent.

10. A method of treating a disease or disorder comprising administering to a subject in need thereof a therapeutically effective amount of at least one compound of claim 1 , wherein the disease or disorder is atherosclerosis, dyslipidemia, diabetes.

11. The method of claim 10 wherein the disease or disorder is atherosclerosis.

12. The method of claim 10 wherein the disease or disorder is diabetes.

13. A composition comprising at least one compound of claim 4 and one or more pharmaceutically acceptable carriers.

14. The composition of claim 13 further comprising at least one additional therapeutic agent.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2022
From: EXELIXIS PATENT COMPANY LLC
To: EXELIXIS, INC.
Reel/Frame 059752/0813 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2019
From: BRISTOL-MYERS SQUIBB COMPANY
To: EXELIXIS PATENT COMPANY LLC
Reel/Frame 048529/0879 →